Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Neuren PharmaceuticalsASX:NEU -0.82%48 EV-to-OCF is 20.93 as of Aug. 19, 2026, which is 21% above its 10-year median of 17.28. GuruFocus rates ASX:NEU with a GF Score™ of 48/100 and a GF Value™ of A$7.94 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 1,408 Biotechnology companies, Neuren Pharmaceuticals ranks worse than 88.85% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Neuren Pharmaceuticals's Enterprise Value is A$2,624.75 Mil.
Neuren Pharmaceuticals's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was A$125.42 Mil. Therefore, Neuren Pharmaceuticals's EV-to-OCF for today is 20.93.
The historical rank and industry rank for Neuren Pharmaceuticals's EV-to-OCF or its related term are showing as below:
ASX:NEU'
s EV-to-OCF Range Over the Past 10 Years
Min: -232.79 Med: 17.28 Max: 862.79
Current: 21.34
During the past 13 years, the highest EV-to-OCF of Neuren Pharmaceuticals was 862.79. The lowest was -232.79. And the median was 17.28.
ASX:NEU's EV-to-OCF is ranked worse than 88.85% of 1408
companies
in the Biotechnology industry
Industry Median: -3.66
vs ASX:NEU: 21.34
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Neuren Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
Neuren Pharmaceuticals's share price for today is A$22.85.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Neuren Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.233.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Neuren Pharmaceuticals's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neuren Pharmaceuticals EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Neuren Pharmaceuticals's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Neuren Pharmaceuticals's EV-to-OCF falls into.
Neuren Pharmaceuticals's current Enterprise Value is A$2,624.75 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Neuren Pharmaceuticals's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was A$125.42 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neuren Pharmaceuticals (ASX:NEU) has a EV-to-OCF of 20.93 as of Aug. 19, 2026. This is 21% above median its historical median of 17.28. According to the industry distribution chart, Neuren Pharmaceuticals ranks #1251 out of 1408 companies in the Biotechnology industry, placing it in the top 88.8%.
Is Neuren Pharmaceuticals' EV-to-OCF too high?
Neuren Pharmaceuticals' current EV-to-OCF of 20.93 is 21% above median its 10-year median of 17.28. Based on the distribution chart, Neuren Pharmaceuticals ranks #1251 out of 1408 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Neuren Pharmaceuticals has a GF Score™ of 48/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Neuren Pharmaceuticals' EV-to-OCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Neuren Pharmaceuticals ranks #1251 out of 1408 companies for EV-to-OCF. This places Neuren Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Neuren Pharmaceuticals's current EV-to-OCF is 20.93, which is 21% above median its own 10-year median of 17.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neuren Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Neuren Pharmaceuticals (ASX:NEU) is currently considered Significantly Overvalued. The stock's GF Value™ is A$7.94, compared to a current price of A$22.85 — trading 187.8% above its estimated fair value. The current EV-to-OCF is 20.93, which is 21% above median its 10-year median of 17.28. Neuren Pharmaceuticals' overall GF Score™ is 48/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Neuren Pharmaceuticals (ASX:NEU), the current EV-to-OCF is 20.93 as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Neuren Pharmaceuticals (ASX:NEU) Overvalued in 2026?
Based on GuruFocus' analysis, Neuren Pharmaceuticals stock appears to be overvalued.
The current stock price of A$22.85 is trading 187.8% above its estimated GF Value™ of A$7.94.
GuruFocus considers Neuren Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for ASX:NEU:
EV-to-OCF: 20.93 (21% above median its 10-year median of 17.28)
GF Value™: A$7.94 vs. price of A$22.85 (187.8% above fair value)
No single metric tells the full story. See the ASX:NEU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Neuren Pharmaceuticals Ltd is a biopharmaceutical company, which engages in the development of new therapies for brain injury, neurodevelopment disorders. Its drugs target symptoms resulting from acute traumatic brain injury, as well as symptoms of chronic conditions, such as Rett syndrome and Fragile X syndrome. The Group has two reportable operating segments, Commercial Products and Research and Development. It derives maximum revenue from Commercial Products.
48GF Score
Get the complete analysis for ASX:NEU
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:NEU has been successfully added to your 
